Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anti PD-1 Plus Postbiotic Versus Anti PD-1 Alone in Locally Advanced or Metastatic, Treatment naïve, Cutaneous Melanoma: a Phase II Randomized Study With Correlative Biomarkers' Analysis:

NCT07050940 is registered in ClinicalTrials.gov with Azienda Ospedaliera di Perugia as lead sponsor.

NCT NCT07050940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07050940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anti PD-1 Plus Postbiotic Versus Anti PD-1 Alone in Locally Advanced or Metastatic, Treatment naïve, Cutaneous Melanoma: a Phase II Randomized Study With Correlative Biomarkers' Analysis:
Lead sponsor
Azienda Ospedaliera di Perugia
Phase
Not applicable
Overall status
Recruiting
Start date
February 1, 2025
Completion date
August 1, 2026
Enrollment
35 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma metastatic